|65.71||+0.2500||+0.38%||Vol 6.96M||1Y Perf 8.19%|
|Apr 19th, 2021 14:34 DELAYED|
|-0.36 -0.55%||- -|
|Target Price||74.30||Analyst Rating||Moderate Buy 1.77|
|Potential %||13.54||Finscreener Ranking||★★+ 48.87|
|Insiders Trans % 3/6/12 mo.||-100/-100/-76||Value Ranking||★★+ 49.45|
|Insiders Value % 3/6/12 mo.||-100/-100/-92||Growth Ranking||★+ 41.80|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-91||Income Ranking||★★★★+ 60.42|
|Market Cap||146.79B||Earnings Rating||Buy|
|Price Range Ratio 52W %||88.92||Earnings Date||29th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Apr 2021|
|Estimated EPS Next Report||1.82|
|EPS Growth Next 5 Years %||7.00|
|Avg. Weekly Volume||9.60M|
|Avg. Monthly Volume||10.72M|
|Avg. Quarterly Volume||12.40M|
Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 65.46 per share at the end of the most recent trading day (a 1.58% change compared to the prior day closing price) with a volume of 14.59M shares and market capitalization of 146.79B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.
The one-year performance of Bristol-Myers Squibb Company stock is 8.19%, while year-to-date (YTD) performance is 5.53%. BMY stock has a five-year performance of -3.3%. Its 52-week range is between 54.07 and 67.16, which gives BMY stock a 52-week price range ratio of 88.92%
Bristol-Myers Squibb Company currently has a PE ratio of -15.50, a price-to-book (PB) ratio of 3.66, a price-to-sale (PS) ratio of 4.41, a price to cashflow ratio of 9.90, a PEG ratio of 2.32, a ROA of -6.94%, a ROC of 1.35% and a ROE of -19.18%. The company’s profit margin is -26.65%, its EBITDA margin is 11.60%, and its revenue ttm is $31.74 Billion , which makes it $14.21 revenue per share.
Of the last four earnings reports from Bristol-Myers Squibb Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.82 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (1.77), with a target price of $74.3, which is +13.54% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bristol-Myers Squibb Company has a dividend yield of 3.13% with a dividend per share of $1.96 and a payout ratio of 273.00%.
Bristol-Myers Squibb Company has a Buy technical analysis rating based on Technical Indicators (ADX : 4.96, ATR14 : 1.41, CCI20 : 225.19, Chaikin Money Flow : 0.17, MACD : 0.62, Money Flow Index : 54.06, ROC : 3.40, RSI : 62.71, STOCH (14,3) : 95.45, STOCH RSI : 1.00, UO : 65.46, Williams %R : -4.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Dubow (Option Excercise at a value of $0), Adam Dubow (Sold 4 100 shares of value $252 283 ), Christopher S. Boerner (Option Excercise at a value of $0), David V. Elkins (Option Excercise at a value of $0), Dinesh C. Paliwal (Buy at a value of $999 966), Elizabeth A. Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 64 840 shares of value $4 052 968 ), Joseph Eid (Option Excercise at a value of $0), Joseph Eid (Sold 5 327 shares of value $340 928 ), Julia A. Haller (Option Excercise at a value of $0), Karen Murphy Santiago (Option Excercise at a value of $0), Louis S. Schmukler (Option Excercise at a value of $0), Louis S. Schmukler (Sold 25 000 shares of value $1 567 000 ), Michael W. Bonney (Option Excercise at a value of $0), Nadim Ahmed (Option Excercise at a value of $0), Paul von Autenried (Option Excercise at a value of $0), Paul von Autenried (Sold 20 003 shares of value $1 255 191 ), Powell Ann Judge (Option Excercise at a value of $0), Rupert Vessey (Option Excercise at a value of $4 360 456), Rupert Vessey (Sold 142 024 shares of value $8 707 026 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sandra Leung (Sold 141 420 shares of value $8 943 401 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.